To examine whether the ability of complement to form soluble immune complexes plays a role in preventing immune complexmediated diseases, we analyzed the capacity of complement to inhibit immune precipitation (1IP) and to solubilize preformed immune aggregates (SOL) in 23 sera of patients with various hypocomplementemic states, and we correlated the results of these studies with the clinical syndromes found in the various patients.
Introduction
The association between complement deficiency and immune complex diseases has become evident over recent years (1) . It is therefore possible that complement has a physiological role in preventing tissue formation or deposition of immune complexes. In vitro, complement can bring about the formation of soluble complexes either by inhibiting their aggregation at the time of the antigen-antibody reaction or by solubilizing preformed immune precipitates (2, 3) . Inhibition of immune precipitation (IIP)' relies predominantly on an intact classical pathway of complement activation, whereas solubilization (SOL) is dependent on the presence of normal alternative pathway function (4) (5) (6) . Both processes result in the formation ofsoluble complexes by the covalent binding of C3 fragments (7, 8) .
Assays have been devised to measure SOL and 1IP in vitro in sera of patients with various immune complex-mediated diseases (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Abnormalities have been found in different diseases, but no attempts have been made to compare these two functions in defined situations in order to determine their biological relevance.
In this study, UIP and SOL were analyzed and compared in various hypocomplementemic sera. The results indicated that alterations in TIP and SOL differ depending on the type of hypocomplementemia. In particular, assays for 1IP revealed rapid and immediate aggregation of complexes in sera with early classical pathway defects, suggesting that such hypocomplementemic states are a favorable ground for the formation ofinsoluble complexes.
Methods
Immune complex model A '25l-bovine serum albumin (BSA; Armour Ltd., Eastbourne, United Kingdom)-rabbit anti-BSA antibody model was used for both SOL and IIP as previously described (3, 6) . Briefly, the IgG fraction of rabbit BSA antiserum was prepared by Na2SO4 salt precipitation. Antibodies crossreacting with human serum albumin (HSA) were removed by immunoadsorption on insolubilized HSA (Sigma Chemical Co., St. Louis, MO) . Thereafter, the rabbit anti-BSA antibody did not react with chloramine T '251-radiolabeled HSA (23) , i.e., did not form soluble or precipitating immune complexes as determined by sucrose density gradient ultracentrifugation (SDGU).
(a) IIP assay. 50 ml oftest serum, 0.5 gg '251I-BSA, and when required, the appropriate additional reagent, were mixed and adjusted to a final volume of 120 ,l with buffer (complement-fixing diluent (CFD): barbitalbuffered saline, pH 7.4, conductivity 14 mmHo; CFD, Oxoid Ltd., Basingstoke, United Kingdom). After a preincubation of 5 min at 37°C, 9 zg of rabbit anti-BSA antibody was added and the incubation carried out at 37°C. 25-ml aliquots were removed after various time intervals, mixed with I ml phosphate-buffered saline (PBS) (pH 7.4, conductivity 14 mmHo; PBS, Oxoid Ltd.) and centrifuged at 3,000 g for 10 min at 4°C. Supernatants and pellets were separated and the radioactivity measured.
(b) SOL assay. Immune 
Purified complement proteins
Clq and C4 were purified according to published methods (24, 25) . Properdin was purified as described by Medicus et al. (26) . The purity of these three proteins was shown by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in the presence and in the absence of reducing agents (27 (Fig.  1 B) . SOL was abolished in the presence of 10 mM EDTA.
The formation of soluble immune complexes by TIP and SOL was studied in various hypocomplementemic sera (Table  I) . These sera were grouped according to their main complement defect: (a) deficiencies (def) of early classical pathway components ( 15 sera); (b) depletion of C3 and properdin def (5 sera); and (c) def of one of the membrane attack complex proteins (3 sera). Immune complexes were measured in all sera, since their presence could interfere with normal complement function. Clq binding material was found in the five patients with cryoglobulinemia (>50% binding), and in Clq and C4 deficient sera (84 and 12% binding, respectively) (normal: <5%).
IIP and SOL assays in sera with depletion or def of early classical pathway components. The major observation was a severe defect in IIP. Initial fast precipitation was evident in most sera, and this was followed by partial redissolution of the complexes ( Fig. 1) . A similar kinetic was observed in normal serum chelated with 10 mM EGTA plus 2 mM Mg, indicating that immediate aggregation was related to the absence of classical pathway function. However, IIP remained normal in two sera: these two exceptions were the sera with Cl inactivator deficiency but without severe classical pathway depletion.
That SOL was possible in these sera was indicated by the partial redissolution of aggregated complexes in the UIP assay, and this was confirmed in the SOL assay: whereas SOL was in the normal range for all 15 sera at 2 h, in most cases this SOL was preceded by a prolonged lag phase compared with normal serum. Fig. 1 B shows the results obtained with the five sera of patients with acquired depletion ofclassical pathway components (paraproteinemia and benign tumor). The four sera in which SOL was not delayed were: the two C l inactivator-deficient sera without classical pathway depletion, C lq-deficient serum, and one serum containing cryoglobulins (patient 12).
To establish that these defects in UIP and SOL were related to absent classical pathway activity, the two assays were repeated in Clq and C4-deficient sera repleted with the missing component. UIP and SOL were restored by repleting C4-deficient serum with purified C4 (Fig. 2) . In separate experiments it was possible to establish that only 1% of C4 (3 ,ug/ml serum) was required to normalize IIP. In addition in the IIP assay, early precipitation of complexes was faster in this serum after chelation with 10 mM EGTA plus 2 mM Mg or with EDTA. Since the macromolecular Cl complex delays immune aggregation, this observation could be due to Cl dissociation after chelation ofcalcium (37) . Furthermore, initial aggregation was faster in C lq deficient than in C4-deficient serum, and there was no difference in the initial aggregation in Clq-deficient serum whether calcium was chelated or not (EGTA-Mg or EDTA). In Clq-deficient serum and in another serum where Clq was diminished predominantly (patient 6), UIP was restored by purified Clq: 15 gg/ml serum (20% of normal) was necessary to normalize IIP in Clq-deficient serum. The immune complexes detected by the Clq binding assay in both sera seem not to have interfered with repletion experiments.
In sera containing cryoglobulins, defective IIP could also have been due to the cryoglobulins rather than hypocomplementemia. We obtained again fresh serum of patient 11 (mixed cryoglobulinemia IgMk-IgG) in which hemolytic C4 was 1% of normal, whereas other complement proteins were less depleted. The IIP assay was performed in the presence of absence of purified C4 (100 and 200% of hemolytic C4). In this serum, kept at 37°C, purified C4 was not consumed after an incubation of 15 min in a control experiment without immune complexes, whereas 80% was consumed when complexes were added. Thus C4 function was restored, and this C4 was activated by BSAanti-BSA complexes. However, IIP was only partially improved; after an incubation of 15 min, the percentage of soluble complexes was 96% in NHS, 70% in the cryoglobulinemic serum, and 75 and 76%, respectively, after repletion with the two concentrations of C4. Since the CH50 of the repleted sera was only 50% of normal, it is clear that complement function has not been fully restored by C4. Thus, hypocomplementemia (here C4 depletion) is at least in part responsible for detective IIP; however, cryoglobulins by themselves could have an additional detrimental role on IIP.
IIP and SOL assays in sera with profound C3 depletion, and in P-deficient serum. SOL was abolished in all sera. By contrast, UIP was only defective: the aggregation of complexes proceeded at a very reduced rate; i.e., >85% were still soluble after 30 min (Fig. 3) . P-deficient serum showed the widest difference between the two assays (Fig. 4) HIP and SOL in membrane attack complex protein def lIP and SOL were normal in sera with C7 or C8 def. Relationship between immune complex size and abnormalities in HIP and SOL. To see whether the differences in UIP and SOL obtained in the various sera could be related to the size of the soluble immune complexes formed, the experiments were repeated and the size of the complexes determined by SDGU after an incubation of 2 h. In normal human serum, UIP and SOL produced complexes of similar size; however, since SOL was not complete (normal: 55%), a fraction ofthe initial insoluble complexes was recovered in the pellets of the ultracentrifuged tubes (Fig. 5) . In patients with early classical pathway depletion or def (group a), the size of the soluble complexes formed was normal in both assays. However, in UIP experiments a fraction of the complexes was recovered in the pellets. This fraction corresponded well to the fraction of insoluble complexes determined by centrifugation at 3,000 g in the UIP assay. After repletion of C4 and Clq in the corresponding deficient sera, no pelleted insoluble complexes were formed. Thus classical pathway defects affected only the proportion of the soluble immune complexes formed but not their size.
In contrast, in the four C3-depleted sera not sustaining any SOL (group b), the complexes formed during IIP were larger than in normal human serum in two, did not form a homogeneous population in one, and aggregated in one (Fig. 6) . The soluble complexes formed in P-deficient serum were larger than those formed in normal serum; however, their size was normalized by repletion with P (Fig. 7) . Thus, alternative pathway dysfunction abolished the formation of normal size soluble complexes. In membrane attack complex def (group c), the size of the soluble complexes was not modified.
Discussion
Several lines of evidence suggest that complement is involved in the elimination of immune complexes. Firstly, complementdeficient states are associated with various types of immune complex diseases (1) . Secondly, complement affects directly the structure of immune complexes either by breaking up insoluble immune aggregates or by maintaining immune complexes soluble at the time of the antigen-antibody reaction (2, 3) . In this study we compared UIP and SOL-the two complement functions that bring about the formation of soluble complexes-in various hypocomplementemic states to see whether defects in for UIP and 25% for SOL.
these two functions could explain the association of complement deficiency and immune complex disease. HIP and SOL were not affected similarly in the various sera tested. Abnormalities in HIP were related to early classical pathway defects, whereas SOL was abolished in the absence of AP function. In Clq and in C4 deficiency, HIP was severely defective mainly in its initial phase; however, immune aggregation was followed by partial redissolution of the complexes, suggesting that the SOL process was intact. This was confirmed in the SOL assay which was only preceded by a prolonged lag phase in C4-deficient serum. That defective classical pathway function was responsible for the incapacity to prevent rapid immune aggregation was demonstrated by repleting the two deficient sera with their respective missing component.
It has been shown that C4 fragments, despite binding to complexes, have little or no capacity to delay immune aggregation (37, 38) . The finding that only 1% hemolytical C4 was sufficient to restore IIP in the C4-deficient serum suggests that the main role ofC4 is to provide an initial C3 convertase attached to the complex so as to obtain immediate AP activation. The relative role of C4 in HIP was also evident in the three patients with Cl inactivator deficiency, since only the patient with profound C4 depletion presented an initial defect in IlP. Macromolecular C I has a direct inhibitory effect on immune aggregation at the time of the antigen-antibody reaction, and this effect is proportional to its concentration (37) . Thus, Clq incorporated in the Cl complex does not only initiate classical pathway activation but directly prevents the immediate aggregation reaction. This Cl effect was probably present in C4-deficient serum, since initial immune aggregation was not as fast as in Clq-deficient serum.
In P-deficient serum, 1IP and SOL were affected very differently. The essential role of Properdin in SOL is well established; however, we wanted to know if a serum deficient in only this component, and in the face ofa reduced immune complex load, whether some SOL would be possible. The results were clear: no significant SOL occurred in any of the experiments done using our immune complex model. This SOL was restored by purified P and was directly proportional to P concentration. The absent SOL contrasted with the capacity ofthis serum to prevent immune precipitation, confirming results obtained with a serum depleted of Properdin (6) . Complement mediated UIP, like SOL, did not require the assembly of the membrane attack complex (C5b to C9), since IIP and SOL were normal in C7 and C8 deficient sera.
In sera of patients with complement-depleted states, alterations in UIP and SOL could be directly related to missing complement function or proteins: early classical pathway depletion correlated with initial defects in UIP and C3 depletion with abolition ofSOL. In the later group, UIP was not as much preserved as in P deficiency: aggregation of complexes could not be prevented completely, but did proceed at a very reduced rate. A similar slow aggregation has been reported previously in serum depleted of C3 with cobra venom factor and in C3-deficient serum (3 In vivo it is likely that complement is continuously involved in the formation of soluble complexes so that the reaction between antigen and antibody does not lead to the formation of insoluble material. Prevention of immune aggregation could allow complexes formed in the extravascular space to diffuse into the lymphatic and blood vessels, and those formed in the blood stream not to deposit in tissues. Furthermore, it has been suggested that C3 binding to the complexes is of major importance for the safe disposal of large soluble complexes (40) . Indeed, in primates, whose erythrocytes have C3b receptors, such complexes have been shown to be delivered to the fixed macrophage system on the surface of erythrocytes.
Clinical indications on the relevance of complement-mediated lIP comes from the strong association between different early classical pathway component deficiencies and immune complex diseases (1) . The Clq-and C4-deficient patients investigated here are no exceptions; most such patients suffer from SLE-like diseases. Interestingly, C3 deficiency is less often associated with immune complex disease than are Clq and C4 deficiencies. The partial delay in immune aggregation could still be protective to some extent. Of particular interest is the observation that lIP is preserved in P-deficient serum: none of the seven patients described to date has an immune complex disease (29, and Sjoholm, A., and P. Spaeth, unpublished observation). This casts some doubts on the possible protective role of SOL, since SOL is abolished in the absence of P. It is therefore likely that in many situations, normal classical pathway function is essential and sufficient to protect the organism against the harmful effects of immune complex formation and deposition in various tissues.
The consequences of acquired defects of complement components are likely to be similar to inherited deficiencies, since comparable defects in lIP are observed. Nephritic factor and profound C3 depletion are associated with membranoproliferative glomerulonephritis type II; however, such patients have no vasculitis. Furthermore, deposits in the glomeruli contain most often C3 fragments but little or no immunoglobulin (41 
